Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 3Phase NA 1Phase 2 1

Status

Completed 19Unknown 8Recruiting 5Terminated 4

Sponsor Class

OTHER 5

Study Type

Interventional 5Observational 1

Sponsor

Conditions

Breast Neoplasms 1324Neoplasms 982Carcinoma, Non-Small-Cell Lung 860Prostatic Neoplasms 724Colorectal Neoplasms 666Lung Neoplasms 551Leukemia, Myeloid, Acute 475Neoplasm Metastasis 434Pancreatic Neoplasms 419Carcinoma, Hepatocellular 407Multiple Myeloma 396Ovarian Neoplasms 392Stomach Neoplasms 379Recurrence 364Squamous Cell Carcinoma of Head and Neck 325Melanoma 294Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Glioblastoma 264Head and Neck Neoplasms 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 234Lymphoma 228Rectal Neoplasms 222Esophageal Neoplasms 222Sarcoma 213Carcinoma, Renal Cell 203Colonic Neoplasms 194Lymphoma, Non-Hodgkin 191

Interventions

Spironolactone 2Progesterone 2Metformin 1Magnesium 1Carnitine 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × Hyperandrogenism × Clear all
NCT07298564 2025-12-23

Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)

Science & Research Islamic Azad University Branch Khozestan

Phase NA Recruiting
84 enrolled

Hirsutism, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism, Dyslipidemias

NCT00929006 2025-08-05

CRM003

University of Virginia

Phase EARLY_PHASE1 Recruiting
36 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT03068910 2025-08-05

CRM008

University of Virginia

Phase EARLY_PHASE1 Recruiting
32 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT04723862 2025-08-05

CBS010

University of Virginia

Phase EARLY_PHASE1 Recruiting
32 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT02647827 2024-10-09

PIAII

Karolinska Institutet

Phase 2 Recruiting
303 enrolled

Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡